Corporate publications | Resources | Media | Grünenthal Group

Innovation is at the heart of everything that we do. It’s the driving force behind new ideas and future therapies.

... Research & Development

For us, innovation goes beyond drug development. Our innovation is built on expert knowledge of disease-pathophysiology’s, understanding of the patient, the use of big data and state-of-the-art technologies such as devices that result in innovative solutions for the patients need.

... Strategy

Our R&D pipeline is a source of great excitement – we currently have several new drug candidates and technologies in different phases of development.

... Pipeline

Our key innovation areas are pain and devices and technologies.

... Focus areas

As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available.

... Clinical trials

Collaboration with the scientific community is central to our R&D strategy. Let’s work together – collaborate with us!

... Collaborate with us

Ambition is welcome at Grünenthal. Whether you’re a world-class scientist or a talented graduate, together we drive cutting-edge research projects and develop products of the future. Grünenthal offers a culture of opportunity. Join us!

... Jobs and career

A distinct culture is central to the wellbeing of any organisation. Be!Grünenthal has been vital in engaging new employees with our business and guiding our daily work.

... Be!Grünenthal

From research scientists and high achieving graduates to experts in marketing and production, our open and inclusive culture helps everyone thrive.

... Meet our people

Corporate Publications

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a € 2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.
Grünenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in approx. 30 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 100 countries and approx. 5,200 employees are working for Grünenthal worldwide. In 2017, Grünenthal achieved revenues of approx. € 1.3 bn.